Purpose Of Review: Our goal is to present the most up-to-date options in the surgical management of drooling in the paediatric population. While the clinical assessment of the drooling child and conservative management options are discussed, this review focuses on the most recent evidence for surgical interventions to treat drooling in children.
Recent Findings: In terms of advances in the management of drooling, further experience and outcomes with the use of botulinum toxin injections is discussed. Moreover, the latest evidence-base for salivary duct ligation and relocation procedures are presented. Finally, the trans-oral approach to submandibular gland excision for the management of drooling may gain popularity through the aim of reducing surgical morbidity.
Summary: The drooling child should be managed with an evidence-based stepwise approach delivered by a multidisciplinary team (MDT). Children with normal neurological development should be treated conservatively through parental reassurance. There are numerous interventions available for the drooling child with impaired neuromuscular development. When conservative measures fail, treatment options include botulinum toxin injections and surgical procedures such as salivary duct ligation, salivary duct relocation and salivary gland excision. Management must be targeted to the individual needs and comorbidities of the child to maximise treatment outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884899 | PMC |
http://dx.doi.org/10.1007/s40136-018-0188-2 | DOI Listing |
Brain Inj
January 2025
Brain Injury Services, Royal Hospital for Neurodisability, London, UK.
Introduction: Sialorrhea may be a consequence of severe acquired brain injury (ABI). Salivary gland botulinum neurotoxin (SG-BoNT) injections can reduce saliva production, but there is limited evidence for their use in ABI.We reviewed the effectiveness, impact on chest infection frequency, and safety of SG-BoNT for sialorrhea in a cohort of patients with severe ABI.
View Article and Find Full Text PDFJ Clin Psychopharmacol
October 2024
TOBB University of Economics and Technology, Faculty of Medicine, Ankara, Turkey.
Background: Clozapine has demonstrated efficacy in treating treatment-resistant schizophrenia; however, it has a wide range of side effects. Sialorrhea is a common side effect of clozapine that causes the patient to withdraw from social life. This review aims to evaluate and summarize the prevalence, mechanism, risk factors, and management of clozapine-associated sialorrhea.
View Article and Find Full Text PDFAnn Otol Rhinol Laryngol
November 2024
Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Objective: Surgical management of head and neck cancer (HNC) can result in significant functional deficits. Large tumors of the oral cavity may require extensive resection and the need for microvascular free-flap reconstruction involving the use of adynamic tissue. This may result in oral incompetence, drooling, and unsatisfactory esthetic outcomes.
View Article and Find Full Text PDFPatient Prefer Adherence
November 2024
Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA.
Purpose: Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia in the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis and myocarditis were identified by pharmacovigilance. VigiBase, the WHO global database, is a cornerstone of international pharmacovigilance efforts for ADR identification during post-marketing surveillance.
View Article and Find Full Text PDFJ Laryngol Otol
November 2024
Department of Paediatric Otolaryngology, Starship Children's Hospital, Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand.
Objective: Drooling or saliva spillage has been explored widely among children with neurodevelopmental conditions. Yet, the approach to drooling in an otherwise developmentally normal child remains unexplored, as it is regarded as self-limiting. Nonetheless, drooling beyond age 4 in the awake stage should raise concern.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!